f products sold894,063900,465(0.7)Selling and administrative 495,878482,2712.8Research and development118,162112,2275.3TOTAL OPERATING COSTSAND EXPENSES1,508,1031,494,9630.9OPERATING INCOME392,089336,75716.4Interest income7,92215,448(48.7)Interest expense(35,029)(29,378)19.2Other income (expense), net714(385)NM INCOME FROM CONTINUING OPERATIONS BEFOREINCOME TAXES365,696322,44213.4Income tax provision95,44773,89829.2INCOME FROM CONTINUING OPERATIONS270,249248,5448.7INCOME FROM DISCONTINUED OPERATIONSNET OF INCOME TAX PROVISION OF$216,336 AND $7,327, RESPECTIVELY355,18714,441NM NET INCOME
$
625,436
$
262,985NM EARNINGS PER SHAREBasic:Income from continuing operations
$
1.38
$
1.1619.0Income from discontinued operations
$
1.81
$
0.07NM Net income (1)
$
3.18
$
1.23NM Diluted:Income from continuing operations
$
1.35
$
1.1418.4Income from discontinued operations
$
1.78
$
0.07NM Net income
$
3.13
$
1.21NM AVERAGE SHARES OUTSTANDINGBasic196,427214,300Diluted199,570217,634NM - Not Meaningful(1) Total per share amounts may not add due to rounding. BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONREVENUES BY SEGMENT AND GEOGRAPHIC AREA(Unaudited; Amounts in thousands)Three Months Ended December 31,20122011% ChangeBD MEDICALUnited States
$
425,366
$
414,6692.6International558,007535,7284.2TOTAL
$
983,373
$
950,3973.5BD DIAGNOSTICSUnited States
$
320,540
$
311,6232.9International331,385309,1207.2TOTAL
$
651,925
$
620,7435.0BD BIOSCIENCESUnited States
$
84,195
$
79,9265.3Internatio
'/>"/>
SOURCE BD (Becton, Dickinson and Company) Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related medicine technology :1.
Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes2.
Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 20123.
JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies4.
Misonix Announces New Distribution Agreement For Panama5.
University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park6.
Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center7.
Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter8.
Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability9.
Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors10.
Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study11.
STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast